New Directions
in New Therapies

Key Market Facts:

  • Approximately 5.2 million people are diagnosed with AD in the U.S.
  • There are 44 million people with AD in the world.
  • The number of people with dementia will more than double in 25 years. 
  • Alzheimer's is the sixth leading cause of death in the United States.
  • One in nine people age 65 and older has Alzheimer's. 
  • Direct health care expenses for AD and other dementias were $214 billion in 2014, which is higher than both heart disease and cancer.
  • The cost of AD and dementia care will be more than $1.2 trillion in 2050.


Even today, there is no cure for Alzheimer's disease (AD); the cause and progression of AD is not well understood and the disease progresses unabated. That's why Wedge Therapeutics is developing a minimally-invasive neurostimulation system that provides a novel way to jump start the neurons in people afflicted with Alzheimer's disease.

Our Sphenoid and Olfactory Nerve Stimulation™ (SONS™*) System can be thought of as a new form of Deep Brain Stimulation (DBS), but with no surgeries, less complications to patients, and a huge cost reduction to the health system.

Wedge believes that the SONS System™ may:

  • Improve the patient's memory
    • Jumpstart the electrical communication between neurons
    • Increase & enhance neurotransmitter activity
    • Increase hormonal output
    • Increase CBV and decrease inflammation
  • Stop or delay the progression of the disease
  • Improve the quality of life

 *SONS is currently designated as an investigational device and limited by U.S. Federal law to investigational use